Targeting beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer's disease

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Lobello, Kasia ^a   Ryan, J Michael ^a   Liu, Enchi ^b   Rippon, Gregory ^a   Black, Ronald ^a  

^a PFIZER INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAN 2401; BAPINEUZUMAB; CAD 106; GANTENERUMAB; PONEZUMAB; SOLANEZUMAB; UNCLASSIFIED DRUG; V 950; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

EID: 84856479445     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/628070     Document Type: Review

References (78)

1. Wimo A., Prince M., World Alzheimer Report 2010: The Global Economic Impact of Dementia 2010 London, UK Alzheimers Disease International
2. Wimo A., Winblad B., Jnsson L., The worldwide societal costs of dementia: estimates for 2009 Alzheimer's and Dementia 2010 6 2 98 103
3. Alzheimer A., ber eine eigenartige Erkrankung der Hirnrinde [On a peculiar disease of the cerebral cortex] Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 1907 64 146 148
4. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356 (Pubitemid 34790756)
5. Caccamo A., Oddo S., Sugarman M. C., Akbari Y., LaFerla F. M., Age- and region-dependent alterations in A -degrading enzymes: implications for A -induced disorders Neurobiology of Aging 2005 26 5 645 654 (Pubitemid 40228756)
6. Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E., Bateman R. J., Decreased clearance of CNS -amyloid in Alzheimer's disease Science 2010 330 6012 1774
7. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D. J., Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proceedings of the National Academy of Sciences of the United States of America 2011 108 14 5819 5824
8. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clinical Pharmacology and Therapeutics 2001 69 3 89 95
9. Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D. P., Bergstrm M., Savitcheva I., Huang G. F., Estrada S., Ausén B., Debnath M. L., Barletta J., Price J. C., Sandell J., Lopresti B. J., Wall A., Koivisto P., Antoni G., Mathis C. A., Lngstrm B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Annals of Neurology 2004 55 3 306 319 (Pubitemid 38269583)
10. Jack C. R. Jr., Lowe V. J., Weigand S. D., Wiste H. J., Senjem M. L., Knopman D. S., Shiung M. M., Gunter J. L., Boeve B. F., Kemp B. J., Weiner M., Petersen R. C., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimers disease Brain 2009 132 5 1355 1365
11. Andreasen N., Blennow K., CSF biomarkers for mild cognitive impairment and early Alzheimer's disease Clinical Neurology and Neurosurgery 2005 107 3 165 173
12. Buerger K., Ewers M., Pirttil T., Zinkowski R., Alafuzoff I., Teipel S. J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 2006 129 11 3035 3041 (Pubitemid 44684523)
13. Schott J. M., Crutch S. J., Frost C., Warrington E. K., Rossor M. N., Fox N. C., Neuropsychological correlates of whole brain atrophy in Alzheimer's disease Neuropsychologia 2008 46 6 1732 1737
14. Wisniewski T., Sigurdsson E. M., Murine models of Alzheimer's disease and their use in developing immunotherapies Biochimica et Biophysica Acta 2010 1802 10 847 859
15. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guldo T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P., Immunization with amyloid- attenuates Alzheimer disease-like pathology in the PDAPP mouse Nature 1999 400 6740 173 177 (Pubitemid 29327547)
16. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G. W., A peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 2000 408 6815 982 985 (Pubitemid 32101645)
17. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., Chishti M. A., Horne P., Heslin D., French J., Mount H. T. J., Nixon R. A., Mercken M., Bergeron C., Fraser P. E., St George-Hyslop P., Westaway D., A peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 2000 408 6815 979 982 (Pubitemid 32101644)
18. Bard F., Cannon C., Barbour R., Burke R. L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T., Peripherally administered antibodies against amyloid -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nature Medicine 2000 6 8 916 919 (Pubitemid 30644751)
19. Wilcock D. M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M. J., Gordon M. N., Morgan D., Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition Journal of Neuroscience 2004 24 27 6144 6151 (Pubitemid 38891105)
20. Zago W., Buttini M., Comery T. A., Neutralization of soluble A species by the N-terminal anti-A antibody 3D6 Proceedings of the International Conference on Alzheimers Parkinsons Diseases March 2011 Barcelona, Spain. Abstract 1537
21. Das P., Howard V., Loosbrock N., Dickson D., Murphy M. P., Golde T. E., Amyloid- immunization effectively reduces amyloid deposition in FcR -/- knock-out mice Journal of Neuroscience 2003 23 24 8532 8538 (Pubitemid 37158753)
22. Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D., Hyman B. T., Non-Fc-mediated mechanisms are involved in clearance of amyloid- in vivo by immunotherapy Journal of Neuroscience 2002 22 18 7873 7878 (Pubitemid 35379092)
23. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., Holtzman D. M., Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8850 8855 (Pubitemid 32678116)
24. Solomon B., Koppel R., Hanan E., Katzav T., Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer -amyloid peptide Proceedings of the National Academy of Sciences of the United States of America 1996 93 1 452 455 (Pubitemid 26038175)
25. Magga J., Puli L., Pihlaja R., Kanninen K., Neulamaa S., Malm T., Hrtig W., Grosche J., Goldsteins G., Tanila H., Koistinaho J., Koistinaho M., Human intravenous immunoglobulin provides protection against A toxicity by multiple mechanisms in a mouse model of Alzheimer's disease Journal of Neuroinflammation 2010 7 90
26. Britschgi M., Olin C. E., Johns H. T., Takeda-Uchimura Y., Lemieux M. C., Rufibach K., Rajadas J., Zhang H., Tomooka B., Robinson W. H., Clark C. M., Fagan A. M., Galasko D. R., Holtzman D. M., Jutel M., Kaye J. A., Lemere C. A., Leszek J., Li G., Peskind E. R., Quinn J. F., Yesavage J. A., Ghiso J. A., Wyss-Coray T., Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2009 106 29 12145 12150
27. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., Oertel W., Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence Drugs 2010 70 5 513 528
28. Bayer A. J., Bullock R., Jones R. W., Wilkinson D., Paterson K. R., Jenkins L., Millais S. B., Donoghue S., Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD Neurology 2005 64 1 94 101 (Pubitemid 40082943)
29. Nicoll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O., Neuropathology of human Alzheimer disease after immunization with amyloid- peptide: a case report Nature Medicine 2003 9 4 448 452 (Pubitemid 36460079)
30. Gilman S., Koller M., Black R. S., Jenkins L., Griffith S. G., Fox N. C., Eisner L., Kirby L., Rovira M. B., Forette F., Orgogozo J. M., Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005 64 9 1553 1562 (Pubitemid 40617691)
31. Orgogozo J. M., Gilman S., Dartigues J. F., Laurent B., Puel M., Kirby L. C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B. F., Boada M., Frank A., Hock C., Subacute meningoencephalitis in a subset of patients with AD after A 42 immunization Neurology 2003 61 1 46 54 (Pubitemid 36818745)
32. Vellas B., Black R., Thal L. J., Fox N. C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M., Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders Current Alzheimer Research 2009 6 2 144 151
33. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., Black R. S., Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis Neurodegenerative Diseases 2008 5 3-4 194 196 (Pubitemid 351347848)
34. Ferrer I., Rovira M. B., Guerra M. L. S., Rey M. J., Costa-Juss F., Neuropathology and pathogenesis of encephalitis following amyloid- immunization in Alzheimer's disease Brain Pathology 2004 14 1 11 20 (Pubitemid 38200585)
35. Fox N. C., Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L., Koller M., Effects of A immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 2005 64 9 1563 1572 (Pubitemid 40617692)
36. Nicoll J. A. R., Barton E., Boche D., Neal J. W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., Seubert P., Schenk D., Holmes C., A species removal after A 42 immunization Journal of Neuropathology and Experimental Neurology 2006 65 11 1040 1048
37. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D., A vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 2005 64 1 129 131 (Pubitemid 40082949)
38. Patton R. L., Kalback W. M., Esh C. L., Kokjohn T. A., van Vickle G. D., Luehrs D. C., Kuo Y. M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A. J., Beach T. G., Castao E. M., Roher A. E., Amyloid- peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis American Journal of Pathology 2006 169 3 1048 1063 (Pubitemid 44411966)
39. Serrano-Pozo A., William C. M., Ferrer I., Uro-Coste E., Delisle M. B., Maurage C. A., Hock C., Nitsch R. M., Masliah E., Growdon J. H., Frosch M. P., Hyman B. T., Beneficial effect of human anti-amyloid- active immunization on neurite morphology and tau pathology Brain 2010 133 5 1312 1327
40. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R. W., Bullock R., Love S., Neal J. W., Zotova E., Nicoll J. A., Long-term effects of A 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial The Lancet 2008 372 9634 216 223 (Pubitemid 351978111)
41. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S. G., Black R. S., Schenk D., Seubert P., A 42 immunization in Alzheimer's disease generates A N-terminal antibodies Annals of Neurology 2005 58 3 430 435 (Pubitemid 41266629)
42. Hagen M., Seubert G. P., Jacobsen S., The A peptide conjugate vaccine, ACC-001, generates N-terminal anti-A antibodies in the absence of A directed T-cell responses Proceedings of the Alzheimers Association International Conference on Alzheimers Disease July 2011 Paris, France. Abstract P2-461
43. Winblad B., Safety, tolerability and immunogenicity of the A immunotherapeutic vaccine CAD106 in a first-in-man study in Alzheimer patients Alzheimer's and Dementia 2008 4 4 T128
44. Winblad B. G., Minthon L., Floesser A., Results of the first-in-man study with the active A Immunotherapy CAD106 in Alzheimer patients Alzheimer's and Dementia 2009 5 4 P113 P114
45. Graf A., Andreasen N., Riviere M. E., Optimization of the treatment regimen with active A immunotherapy CAD106 in alzheimer patients Alzheimer's and Dementia 2010 6 4 S532
46. Savage M. J., Wu G., McCampbell A., A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of abeta peptide species Alzheimer's and Dementia 2010 6 4 S142
47. Schneeberger A., Mandler M., Otava O., Zauner W., Mattner F., Schmidt W., Development of AFFITOPE vaccines for Alzheimer's disease (AD)from concept to clinical testing Journal of Nutrition, Health and Aging 2009 13 3 264 267
48. Schneeberger A., Mandler M., Zauner W., Development of AFFITOPE vaccines for Alzheimer's disease Alzheimer's and Dementia 2010 6 4 S584 S585
49. Black R. S., Sperling R. A., Safirstein B., Motter R. N., Pallay A., Nichols A., Grundman M., A single ascending dose study of bapineuzumab in patients with alzheimer disease Alzheimer Disease and Associated Disorders 2010 24 2 198 203
50. Sperling R. A., Jack C. R. Jr., Black S. E., Frosch M. P., Greenberg S. M., Hyman B. T., Scheltens P., Carrillo M. C., Thies W., Bednar M. M., Black R. S., Brashear H. R., Grundman M., Siemers E. R., Feldman H. H., Schindler R. J., Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimer's and Dementia 2011 7 4 367 385
51. Salloway S., Sperling R., Gilman S., Fox N. C., Blennow K., Raskind M., Sabbagh M., Honig L. S., Doody R., Van Dyck C. H., Mulnard R., Barakos J., Gregg K. M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 24 2061 2070
52. Blennow K., Zetterberg H., Wei J., Liu E., Black R., Grundman M., Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease Alzheimer's and Dementia 2010 6 4 S134 S135
53. Chalmers K., Wilcock G. K., Love S., APOE 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A protein Neuropathology and Applied Neurobiology 2003 29 3 231 238 (Pubitemid 36718171)
54. Crean S., Ward A., Mercaldi C. J., Collins J. M., Cook M. N., Baker N. L., Arrighi H. M., Apolipoprotein E 4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis Dementia and Geriatric Cognitive Disorders 2011 31 1 20 30
55. Kinnecom C., Lev M. H., Wendell L., Smith E. E., Rosand J., Frosch M. P., Greenberg S. M., Course of cerebral amyloid angiopathy-related inflammation Neurology 2007 68 17 1411 1416 (Pubitemid 46661556)
56. Eng J. A., Frosch M. P., Choi K., Rebeck G. W., Greenberg S. M., Clinical manifestations of cerebral amyloid angiopathy-related inflammation Annals of Neurology 2004 55 2 250 256 (Pubitemid 38167002)
57. Rinne J. O., Brooks D. J., Rossor M. N., Fox N. C., Bullock R., Klunk W. E., Mathis C. A., Blennow K., Barakos J., Okello A. A., de LIano S. R. M., Liu E., Koller M., Gregg K. M., Schenk D., Black R., Grundman M., 11C-PiB PET assessment of change in fibrillar amyloid- load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study The Lancet Neurology 2010 9 4 363 372
58. Bacskai B. J., Frosch M. P., Freeman S. H., Raymond S. B., Augustinack J. C., Johnson K. A., Irizarry M. C., Klunk W. E., Mathis C. A., DeKosky S. T., Greenberg S. M., Hyman B. T., Growdon J. H., Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report Archives of Neurology 2007 64 3 431 434 (Pubitemid 46425701)
59. Johnson K. A., Gregas M., Becker J. A., Kinnecom C., Salat D. H., Moran E. K., Smith E. E., Rosand J., Rentz D. M., Klunk W. E., Mathis C. A., Price J. C., DeKosky S. T., Fischman A. J., Greenberg S. M., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Annals of Neurology 2007 62 3 229 234 (Pubitemid 47525398)
60. Siemers E. R., Friedrich S., Dean R. A., Gonzales C. R., Farlow M. R., Paul S. M., Demattos R. B., Safety and changes in plasma and cerebrospinal fluid amyloid after a single administration of an amyloid monoclonal antibody in subjects with Alzheimer disease Clinical Neuropharmacology 2010 33 2 67 73
61. Goto T., Fujikoshi S., Uenaka K., Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study Alzheimer's and Dementia 2010 6 4 S308
62. DeMattos R. B., Racke M. M., Gelfanova V., Identification, characterization, and comparison of amino-terminally truncated A 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment Alzheimer's and Dementia 2009 5 4 P156 P157
63. DeMattos R. B., Racke M., Gelfanova V., Characterization of amino-terminally truncated Abeta-42 peptides in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment Alzheimer's and Dementia 2010 6 4 S542
64. Siemers E. R., Demattos R. B., Stuart F., Use of a monoclonal anti-A antibody with biochemical and imaging biomarkers to determine amyloid plaque load in patients with Alzheimer's disease (AD) and control subjects Proceedings of the 61st Annual Meeting of the American Association of Neurology April 2009 Seattle, Wash, USA. Abstract IN3-2.009
65. Siemers E. R., Dean R. A., Lachno D. R., Measurement of cerebrospinal fluid total tau and phospho-tau in phase 2 trials of therapies targeting A Alzheimer's and Dementia 2009 5 4 P258
66. Siemers E., Biochemical biomarkers as endpoints in clinical trials: applications in phase 1, 2 and 3 studies Alzheimer's and Dementia 2009 5 4 P95
67. Burstein A. H., Zhao Q., Ross J., Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer's disease Alzheimer's and Dementia 2010 6 4 S585
68. Landen J. W., Zhao Q., Cohen S., Safety and pharmacokinetics following a single infusion of the anti-amyloid monoclonal antibody ponezumab (PF-04360365) in patients with mild-to-moderate Alzheimer's disease: final results Alzheimer's and Dementia 2010 6 4 e57
69. Zhao Q., Landen J., Burstein A. H., Pharmacokinetics and pharmacodynamics of ponezumab (PF-04360365) following a single-dose intravenous infusion in patients with mild to moderate Alzheimer's disease Alzheimer's and Dementia 2010 6 4 S143
70. Nicholas T., Knebel W., Gastonguay M. R., Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease Alzheimer's and Dementia 2009 5 4 P253
71. Wood K. M., McCush F., Conboy J. J., IP/MS analysis of human CSF A following a single dose of the C-terminal anti-A antibody ponezumab (PF-04360365) to Alzheimer patients Alzheimer's and Dementia 2010 6 4 S311
72. Fujimoto Y., Miyoshi I., Ishibashi T., Safety of the anti-amyloid monoclonal antibody ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: preliminary results Alzheimer's and Dementia 2010 6 4 S310
73. Zhao Q., Abe S., Miyoshi I., Pharmacokinetics of ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: preliminary results Alzheimer's and Dementia 2010 6 4 S305
74. Eisai Co., Ltd., Eisai announces the start of the first clinical study of BAN2401, a novel monoclonal antibody targeting the neurotoxic protofibrils believed to cause Alzheimer's disease. [press release], Eisai Co., Ltd., 2010, http://www.eisai.com/news/enews201044pdf.pdf
75. Dodel R. C., Du Y., Depboylu C., Hampel H., Frlich L., Haag A., Hemmeter U., Paulsen S., Teipel S. J., Brettschneider S., Spottke A., Nlker C., Mller H. J., Wei X., Farlow M., Sommer N., Oertel W. H., Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry 2004 75 10 1472 1474 (Pubitemid 39279821)
76. Relkin N. R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R. W., Younkin S., Younkin L., Schiff R., Weksler M. E., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiology of Aging 2009 30 11 1728 1736
77. Fillit H., Hess G., Hill J., Bonnet P., Toso C., IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders Neurology 2009 73 3 180 185
78. Tsakanikas D., Relkin N., Neuropsychological outcomes following 18-months of uninterrupted intravenous immunoglobulin (IVIg) treatment in patients with Alzheimer's disease (AD) Proceedings of the 62nd Annual Meeting of the American Academy of Neurology April 2010 Toronto, Ontario, Canada. Abstract S34.005